234 related articles for article (PubMed ID: 21353324)
21. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
23. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.
Vermeij J; Teugels E; Bourgain C; Xiangming J; in 't Veld P; Ghislain V; Neyns B; De Grève J
BMC Cancer; 2008 Jan; 8():3. PubMed ID: 18182111
[TBL] [Abstract][Full Text] [Related]
24. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
25. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
Chantranuwat C; Sriuranpong V; Huapai N; Chalermchai T; Leungtaweeboon K; Voravud N; Mutirangura A
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S322-9. PubMed ID: 16623049
[TBL] [Abstract][Full Text] [Related]
26. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
[TBL] [Abstract][Full Text] [Related]
27. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
28. Absence of the ERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients.
Lee JW; Soung YH; Kim SY; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2005 Sep; 116(4):652-3. PubMed ID: 15825173
[No Abstract] [Full Text] [Related]
29. Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.
Weiler D; Diebold J; Strobel K; Aebi S; Gautschi O
J Thorac Oncol; 2015 Apr; 10(4):e16-7. PubMed ID: 25789838
[No Abstract] [Full Text] [Related]
30. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Pelosi G; Pellegrinelli A; Fabbri A; Tamborini E; Perrone F; Settanni G; Busico A; Picciani B; Testi MA; Militti L; Maisonneuve P; Valeri B; Sonzogni A; Proto C; Garassino M; De Braud F; Pastorino U
Virchows Arch; 2016 Jun; 468(6):651-62. PubMed ID: 27056568
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Potential of Afatinib for Cancers with
Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
[TBL] [Abstract][Full Text] [Related]
32. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
[TBL] [Abstract][Full Text] [Related]
33. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
[TBL] [Abstract][Full Text] [Related]
34. Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations.
Peterson MR; Piao Z; Bazhenova LA; Weidner N; Yi ES
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):242-7. PubMed ID: 17721266
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
[TBL] [Abstract][Full Text] [Related]
36. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
Takuwa T; Tanaka F; Yoneda K; Torii I; Hashimoto M; Okumura Y; Matsumoto S; Kondo N; Hasegawa S
Lung Cancer; 2010 Jun; 68(3):498-500. PubMed ID: 20307913
[TBL] [Abstract][Full Text] [Related]
38. Somatic mutations of the HER2 in metastatic breast cancer.
Fang Y; Jiang Y; Wang X; Yang X; Gao Y; Wang J
Tumour Biol; 2014 Dec; 35(12):11851-4. PubMed ID: 25326805
[TBL] [Abstract][Full Text] [Related]
39. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
Mar N; Vredenburgh JJ
Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
[TBL] [Abstract][Full Text] [Related]
40. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.
Bekaii-Saab T; Williams N; Plass C; Calero MV; Eng C
BMC Cancer; 2006 Dec; 6():278. PubMed ID: 17150109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
